AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31584032 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary tips
Number of subjects: 34
Study 31584032 — intervention group
Group type: COMPARATOR
Intervention: Disposable needle
Number of subjects: 34
Study 31584032 — intervention group
Group type: COMPARATOR
Intervention: Pastinject
Number of subjects: 34
Study 30215460 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral TAP block using 40 mL 0.25% bupivacaine
Number of subjects: 88
Study 30215460 — intervention group
Group type: COMPARATOR
Intervention: Standard analgesia protocol without TAP block
Number of subjects: 88
Study 27184353 — intervention group
Group type: EXPERIMENTAL
Intervention: Edwards Sapien 3 (ES3) valve
Number of subjects: 209
Study 27184353 — intervention group
Group type: COMPARATOR
Intervention: Edwards Sapien XT (ESXT) valve
Number of subjects: 209
Study 24448735 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward-related stop trials
Number of subjects: 0
Study 24448735 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward availability
Number of subjects: 0
Study 24448735 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward information
Number of subjects: 0
Study 22823027 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 36
Study 22823027 — intervention group
Group type: COMPARATOR
Intervention: Continued protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI)
Number of subjects: 36
Study 19106322 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding promotion intervention
Number of subjects: 17046
Study 19106322 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 17046
Study 17980239 — intervention group
Group type: EXPERIMENTAL
Intervention: Detergent and chlorhexidine‐alcohol (A)
Number of subjects: 50
Study 17980239 — intervention group
Group type: COMPARATOR
Intervention: Detergent (B)
Number of subjects: 50
Study 15492316 — intervention group
Group type: EXPERIMENTAL
Intervention: AGTR2 G1675A polymorphism
Number of subjects: 221
Study 15492316 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE D/I polymorphism
Number of subjects: 221
Study 15492316 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium excretion
Number of subjects: 221
Study 15492316 — intervention group
Group type: COMPARATOR
Intervention: AGTR1 A1166C polymorphism
Number of subjects: 221
Study 15492316 — intervention group
Group type: EXPERIMENTAL
Intervention: AGTR2 polymorphism
Number of subjects: 221
Study 12017948 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of fenticonazole nitrate intravaginal ovules
Number of subjects: 80
Study 12017948 — intervention group
Group type: COMPARATOR
Intervention: 400 mg of myconazole vaginal ovules
Number of subjects: 80
Study 10570201 — intervention group
Group type: EXPERIMENTAL
Intervention: T2* magnetic resonance microscopy (MRM)
Number of subjects: 8
Study 10570201 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion magnetic resonance microscopy (MRM)
Number of subjects: 8
Study 10570201 — intervention group
Group type: COMPARATOR
Intervention: Nondemented controls
Number of subjects: 8
Study 7776934 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase (2.5 mg once daily)
Number of subjects: 3
Study 7776934 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily)
Number of subjects: 3
Study 1983214 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oxatomide gel 5%
Number of subjects: 41
Study 1983214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 112068 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg
Number of subjects: 60
Study 112068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31796263 — intervention group
Group type: EXPERIMENTAL
Intervention: Previsit educational materials about individual insurance plans
Number of subjects: 100
Study 31796263 — intervention group
Group type: COMPARATOR
Intervention: No previsit educational materials (control group)
Number of subjects: 100
Study 31255395 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (300 mg)
Number of subjects: 24
Study 31255395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28093837 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose simulation education with structured debriefing and verbal feedback
Number of subjects: 30
Study 28093837 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 30
Study 25583184 — intervention group
Group type: EXPERIMENTAL
Intervention: Parachute
Number of subjects: 13
Study 25583184 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand paddles + parachute
Number of subjects: 13
Study 25583184 — intervention group
Group type: COMPARATOR
Intervention: Hand paddles
Number of subjects: 13
Study 25583184 — intervention group
Group type: COMPARATOR
Intervention: Without equipment
Number of subjects: 13
Study 23998969 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3‐FFA 2 g/d
Number of subjects: 647
Study 23998969 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3‐FFA 4 g/d
Number of subjects: 647
Study 23998969 — intervention group
Group type: COMPARATOR
Intervention: Control (olive oil [OO] 4 g/d)
Number of subjects: 647
Study 21871414 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Number of subjects: 24
Study 21871414 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 24
Study 19233338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular suppression during spatial serial recall task
Number of subjects: 0
Study 19233338 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulatory suppression combined with spatial serial recall task
Number of subjects: 0
Study 17279428 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunt Design Trial
Number of subjects: 0
Study 17279428 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Shunt Insertion Trial
Number of subjects: 0
Study 15521903 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on melatonin
Number of subjects: 31
Study 15521903 — intervention group
Group type: COMPARATOR
Intervention: Add-on placebo
Number of subjects: 31
Study 15159366 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) identified by physician reviewers
Number of subjects: 3745
Study 15159366 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventable adverse events
Number of subjects: 3745
Study 15159366 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events leading to death
Number of subjects: 3745
Study 15159366 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional hospital days associated with AEs
Number of subjects: 3745
Study 15159366 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of age between patients with and without AEs
Number of subjects: 3745
Study 10365191 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment (CBT)
Number of subjects: 32
Study 10365191 — intervention group
Group type: COMPARATOR
Intervention: Interactional Treatment (IT)
Number of subjects: 32
Study 7495248 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with beta-carotene, vitamin E, and selenium
Number of subjects: 30000
Study 7495248 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation with 14 vitamins and 12 minerals at two to three times the US RDA
Number of subjects: 30000
Study 7495248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30000
Study 1783363 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amiloride (2 x 2.5 mg) and long‐acting furosemide (2 x 10 mg)
Number of subjects: 12
Study 1783363 — intervention group
Group type: COMPARATOR
Intervention: Amiloride (5 mg) and furosemide (20 mg)
Number of subjects: 12
Study 6813814 — intervention group
Group type: EXPERIMENTAL
Intervention: External pneumatic calf compression (EPCC)
Number of subjects: 28
Study 6813814 — intervention group
Group type: EXPERIMENTAL
Intervention: EPCC combined with aspirin (300 mg bid) and dipyridamole (75 mg tid)
Number of subjects: 28
Study 6813814 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients (previous study)
Number of subjects: 28
Study 6813814 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group (EPCC and ASA/dip)
Number of subjects: 28
Study 31993943 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily tacrolimus
Number of subjects: 242
Study 31993943 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily cyclosporine
Number of subjects: 242
Study 31794625 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-fraction 8-Gy radiotherapy (n=345)
Number of subjects: 686
Study 31794625 — intervention group
Group type: COMPARATOR
Intervention: Multifraction 20 Gy in 5 fractions (n=341)
Number of subjects: 686
Study 31794625 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-fraction 8-Gy radiotherapy
Number of subjects: 686
Study 31794625 — intervention group
Group type: COMPARATOR
Intervention: Multifraction 20 Gy in 5 fractions
Number of subjects: 686
Study 28215837 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid sclerotherapy with Y connector (Group A)
Number of subjects: 91
Study 28215837 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid sclerotherapy direct to cannula (Group B)
Number of subjects: 91
Study 28215837 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy direct to cannula (Group C)
Number of subjects: 91
Study 28215837 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 91
Study 26360770 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin
Number of subjects: 115
Study 26360770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 24160570 — intervention group
Group type: EXPERIMENTAL
Intervention: Sm(avg) obtained by spectral pulse wave Tissue Doppler Imaging (pwTDI) from the lateral and septal sites of the mitral annulus.
Number of subjects: 313
Study 24160570 — intervention group
Group type: COMPARATOR
Intervention: Simpson's rule for assessing EF.
Number of subjects: 313
Study 21351127 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 50-300 U
Number of subjects: 313
Study 21351127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 21351127 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA ≥100 U
Number of subjects: 313
Study 21351127 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 150, 200, and 300 U
Number of subjects: 313
Study 21351127 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA >150 U
Number of subjects: 313
Study 21351127 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 313
Study 19664568 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 15603
Study 19664568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15603
Study 19664568 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawers
Number of subjects: 15603
Study 18183080 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-minute alcohol health education session
Number of subjects: 71
Study 18183080 — intervention group
Group type: COMPARATOR
Intervention: Health education regarding smoking
Number of subjects: 71
Study 15085948 — intervention group
Group type: EXPERIMENTAL
Intervention: Community liaison pharmacy service intervention
Number of subjects: 162
Study 15085948 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 162
Study 11811547 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (200 mg of D‐alpha‐tocopheryl acetate daily)
Number of subjects: 520
Study 11811547 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg of slow release ascorbate daily)
Number of subjects: 520
Study 11811547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study 9515998 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced sodium intake
Number of subjects: 975
Study 9515998 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 975
Study 9515998 — intervention group
Group type: COMPARATOR
Intervention: Reduced sodium intake alone
Number of subjects: 975
Study 9515998 — intervention group
Group type: COMPARATOR
Intervention: Weight loss alone
Number of subjects: 975
Study 9515998 — intervention group
Group type: COMPARATOR
Intervention: Reduced sodium intake and weight loss combined
Number of subjects: 975
Study 9515998 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 975
Study 7775548 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined perioperative infusion of nifedipine and metoprolol (NM)
Number of subjects: 70
Study 7775548 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine only (N)
Number of subjects: 70
Study 30125529 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 360
Study 30125529 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 360
Study 27025986 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone ER (Xtampza ER)
Number of subjects: 193
Study 27025986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 24955456 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 181
Study 24955456 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 181
Study 24301248 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% spray (CPS)
Number of subjects: 0
Study 24301248 — intervention group
Group type: COMPARATOR
Intervention: Vehicle spray
Number of subjects: 0
Study 20950697 — intervention group
Group type: EXPERIMENTAL
Intervention: Start To Run program (10 weeks)
Number of subjects: 19
Study 20950697 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 19
Study 18335118 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 20 ml of honey before and after radiation therapy
Number of subjects: 40
Study 18335118 — intervention group
Group type: COMPARATOR
Intervention: Rinsing with 20 ml of saline before and after radiation therapy
Number of subjects: 40
Study 17140970 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oral sildenafil
Number of subjects: 53
Study 17140970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 14698783 — intervention group
Group type: EXPERIMENTAL
Intervention: [(99m)Tc]DTPA-mannosyl-dextran (0.2 nmol)
Number of subjects: 24
Study 14698783 — intervention group
Group type: EXPERIMENTAL
Intervention: [(99m)Tc]DTPA-mannosyl-dextran (1.0 nmol)
Number of subjects: 24
Study 14698783 — intervention group
Group type: EXPERIMENTAL
Intervention: [(99m)Tc]DTPA-mannosyl-dextran (5.0 nmol)
Number of subjects: 24
Study 14698783 — intervention group
Group type: COMPARATOR
Intervention: Filtered [(99m)Tc]sulfur colloid
Number of subjects: 24
Study 14698783 — intervention group
Group type: EXPERIMENTAL
Intervention: [(99m)Tc]DTPA-mannosyl-dextran (all doses)
Number of subjects: 24
Study 10714909 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day-Estradiol patch (50 microg estradiol per day)
Number of subjects: 186
Study 10714909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 9187443 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy (IF-RT) given to 90% of patients in partial remission (PR) after chemotherapy.
Number of subjects: 493
Study 9187443 — intervention group
Group type: COMPARATOR
Intervention: No further treatment for patients in complete remission (CR) after chemotherapy.
Number of subjects: 493
Study 8235775 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 55
Study 8235775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 3516622 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (0.325 g/kg)
Number of subjects: 12
Study 3516622 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (0.325 g/kg)
Number of subjects: 12
Study 3516622 — intervention group
Group type: COMPARATOR
Intervention: Control (water only)
Number of subjects: 12
Study 3516622 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark bread (2 BU) with butter and water
Number of subjects: 12
Study 3516622 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (1 BU substitution)
Number of subjects: 12
Study 3516622 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol (1 BU substitution)
Number of subjects: 12
Study 31023318 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative systemic therapy and CRS‐HIPEC
Number of subjects: 358
Study 31023318 — intervention group
Group type: COMPARATOR
Intervention: Upfront CRS‐HIPEC alone
Number of subjects: 358
Study 30095746 — intervention group
Group type: EXPERIMENTAL
Intervention: Early continuous positive airways pressure
Number of subjects: 42
Study 30095746 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 42
Study 27310943 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment for BDII for 12 weeks
Number of subjects: 117
Study 25212646 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy
Number of subjects: 440
Study 25212646 — intervention group
Group type: COMPARATOR
Intervention: Standard PCI
Number of subjects: 440
Study 25212646 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined clinical endpoint
Number of subjects: 440
Study 22033719 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative Reconstruction (IR) at 275 mAs (15% dose reduction)
Number of subjects: 90
Study 22033719 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative Reconstruction (IR) at 225 mAs (30% dose reduction)
Number of subjects: 90
Study 22033719 — intervention group
Group type: COMPARATOR
Intervention: Filtered Back-Projection (FBP) at 320 mAs (standard dose)
Number of subjects: 90
Study 22033719 — intervention group
Group type: COMPARATOR
Intervention: Filtered Back-Projection (FBP) at 275 mAs (15% dose reduction)
Number of subjects: 90
Study 22033719 — intervention group
Group type: COMPARATOR
Intervention: Filtered Back-Projection (FBP) at 225 mAs (30% dose reduction)
Number of subjects: 90
Study 20148254 — intervention group
Group type: COMPARATOR
Intervention: 25‐G Quincke type spinal needle
Number of subjects: 216
Study 20148254 — intervention group
Group type: EXPERIMENTAL
Intervention: 29‐G Quincke type spinal needle
Number of subjects: 216
Study 20148254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory patients
Number of subjects: 216
Study 20148254 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 216
Study 19338490 — intervention group
Group type: EXPERIMENTAL
Intervention: C2 levels in schistosomal group (511 ‐/+ 118 nmol/L)
Number of subjects: 100
Study 19338490 — intervention group
Group type: EXPERIMENTAL
Intervention: C2.5 levels in schistosomal group (730 ‐/+ 215 nmol/L)
Number of subjects: 100
Study 19338490 — intervention group
Group type: EXPERIMENTAL
Intervention: C2.5
Number of subjects: 100
Study 15674316 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium group (LS)
Number of subjects: 29
Study 15674316 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 29
Study 11907307 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ligatures
Number of subjects: 33
Study 11907307 — intervention group
Group type: EXPERIMENTAL
Intervention: Powerchain
Number of subjects: 33
Study 11907307 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel-titanium springs
Number of subjects: 33
Study 10550139 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of cytokeratin 18-positive cells in bone marrow
Number of subjects: 287
Study 10550139 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative detection of cells containing cytokeratin 18
Number of subjects: 287
Study 8540794 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular KAFOs
Number of subjects: 9
Study 8540794 — intervention group
Group type: COMPARATOR
Intervention: Original KAFOs
Number of subjects: 9
Study 2185452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil (1 gm, single-dose)
Number of subjects: 200
Study 2185452 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (base or stearate)
Number of subjects: 200
Study 2185452 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (high-dose, 1-day regimen)
Number of subjects: 200
Study 2185452 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 200
Study 2185452 — intervention group
Group type: COMPARATOR
Intervention: Control group (no peritreatment antibiotics)
Number of subjects: 200
Study 381887 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin 60 mg/M2 daily X 3, cytosine arabinoside and thioguanine 100 mg/M2 each every 12 hours until marrow hypoplasia achieved
Number of subjects: 523
Study 381887 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day course of daunorubicin 100 mg/M2 on day 1, cytosine arabinoside plus thioguanine 100 mg/M2 every 12 hours for five days
Number of subjects: 523
Study 381887 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine 100 mg/M2 daily
Number of subjects: 523
Study 381887 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-thioguanine 100 mg/M2 daily
Number of subjects: 523
Study 381887 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/M2 of both 6-mercaptopurine and 6-thioguanine daily
Number of subjects: 523
Study 31878810 — intervention group
Group type: EXPERIMENTAL
Intervention: hEGH gel (Regen-D 150)
Number of subjects: 50
Study 31878810 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 50
Study 30836366 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day PEG-3350 with bisacodyl (PEG-B)
Number of subjects: 124
Study 30836366 — intervention group
Group type: COMPARATOR
Intervention: 3-day sennosides
Number of subjects: 124
Study 29201144 — intervention group
Group type: EXPERIMENTAL
Intervention: Interspinous Dynamic Stabilization System (IDSS)
Number of subjects: 67
Study 29201144 — intervention group
Group type: COMPARATOR
Intervention: Posterior Lumbar Interbody Fusion (PLIF)
Number of subjects: 67
Study 25657075 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral positioning (LiN)
Number of subjects: 218
Study 25657075 — intervention group
Group type: COMPARATOR
Intervention: Conventional positioning (CON)
Number of subjects: 218
Study 24227660 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 50 mg
Number of subjects: 376